2026-2027 Foot and Ankle Journal Club, Course #27D26

Participants meet every month to review and discuss the current months edition of foot and ankle international journal. The aim is to expand medical knowledge in the field of foot and ankle surgery, maintain competence and up-to-date implication of evidence-based practice in foot and ankle surgery.

Download Announcement

1. Apply current evidence-based guidelines and literature to evaluate and manage foot and ankle conditions, selecting appropriate surgical or non-surgical treatments to improve patient outcomes.

The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation Statement: The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

University of Oklahoma Equal Opportunity / Non-Discrimination Statement: The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.
 
To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at link.ou.edu/reportingform.
 
Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit www.ou.edu/eoo.

Accommodation Statement:
Accommodations on the basis of disability are available by contacting (insert Course Contact) at (405) xxx-xxxx or (insert email address) as soon as possible.

Acknowledgement of Commercial and In-Kind Support:
Commercial support is financial, or in-kind, contributions given by a ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. 

Appropriate acknowledgement of all commercial and in-kind support will be given at the time of the educational activity.

Disclaimer Statement:
Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty and Presenters Disclosure: 
It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also disclose discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s). 

Mitigation of Relevant Financial Relationships